CN1215847C - 含磷酸川芎嗪的渗透泵控释制剂及其制备方法 - Google Patents
含磷酸川芎嗪的渗透泵控释制剂及其制备方法 Download PDFInfo
- Publication number
- CN1215847C CN1215847C CN 02156892 CN02156892A CN1215847C CN 1215847 C CN1215847 C CN 1215847C CN 02156892 CN02156892 CN 02156892 CN 02156892 A CN02156892 A CN 02156892A CN 1215847 C CN1215847 C CN 1215847C
- Authority
- CN
- China
- Prior art keywords
- controlled releasing
- ligustrazine phosphate
- releasing penetrant
- active substance
- label
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 6
- KWWLGXNRLABSMP-UHFFFAOYSA-N phosphoric acid;2,3,5,6-tetramethylpyrazine Chemical compound OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C KWWLGXNRLABSMP-UHFFFAOYSA-N 0.000 title claims description 36
- 239000011248 coating agent Substances 0.000 claims abstract description 20
- 238000000576 coating method Methods 0.000 claims abstract description 20
- 239000013543 active substance Substances 0.000 claims abstract description 17
- 239000010408 film Substances 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 239000010409 thin film Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 14
- 238000013270 controlled release Methods 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 229920001353 Dextrin Polymers 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 11
- 235000019425 dextrin Nutrition 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 11
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 229920002301 cellulose acetate Polymers 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 238000012946 outsourcing Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 238000005273 aeration Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000013557 residual solvent Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 14
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract 2
- 229940126589 solid medicine Drugs 0.000 abstract 2
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005553 drilling Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- RQKFOGXUTRDQPB-UHFFFAOYSA-N hydron;2,3,5,6-tetramethylpyrazine;chloride Chemical compound Cl.CC1=NC(C)=C(C)N=C1C RQKFOGXUTRDQPB-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- -1 sieve Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02156892 CN1215847C (zh) | 2002-12-20 | 2002-12-20 | 含磷酸川芎嗪的渗透泵控释制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02156892 CN1215847C (zh) | 2002-12-20 | 2002-12-20 | 含磷酸川芎嗪的渗透泵控释制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1421207A CN1421207A (zh) | 2003-06-04 |
CN1215847C true CN1215847C (zh) | 2005-08-24 |
Family
ID=4752855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02156892 Expired - Fee Related CN1215847C (zh) | 2002-12-20 | 2002-12-20 | 含磷酸川芎嗪的渗透泵控释制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1215847C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100420437C (zh) * | 2006-09-30 | 2008-09-24 | 中国药科大学 | 磷酸川芎嗪缓释微丸及制备方法 |
CN101269049B (zh) * | 2008-04-25 | 2012-01-25 | 广东药学院 | 磷酸川芎嗪微孔渗透泵控释片及其制备方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100410279C (zh) * | 2004-05-28 | 2008-08-13 | 北京理工大学 | 聚酸类川芎嗪酯及其制备方法 |
CN101991614A (zh) * | 2010-09-13 | 2011-03-30 | 吴赣英 | 一种复方发酵虫草菌粉(蝙蝠蛾拟青霉Cs-4菌粉)组合药物及其制备 |
CN108815128B (zh) * | 2018-05-25 | 2022-01-07 | 广东药科大学 | 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法 |
CN111450072B (zh) * | 2020-05-07 | 2022-07-15 | 江苏艾立康医药科技有限公司 | 一种替格瑞洛控释片及其制备方法 |
-
2002
- 2002-12-20 CN CN 02156892 patent/CN1215847C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100420437C (zh) * | 2006-09-30 | 2008-09-24 | 中国药科大学 | 磷酸川芎嗪缓释微丸及制备方法 |
CN101269049B (zh) * | 2008-04-25 | 2012-01-25 | 广东药学院 | 磷酸川芎嗪微孔渗透泵控释片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1421207A (zh) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101435242B1 (ko) | 간염치료용 실리비닌 성분 | |
US20080089937A1 (en) | Controlled release drug compositions and preparation methods | |
KR20110042366A (ko) | 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용 | |
JPH032115A (ja) | 持続放出性薬剤学的ペレット組成物 | |
CN104857515A (zh) | 一种控释给药的药芯组合物以及包含该药芯组合物的渗透泵制剂 | |
JPH0798748B2 (ja) | ベラパミルの投与用製剤 | |
CN1215847C (zh) | 含磷酸川芎嗪的渗透泵控释制剂及其制备方法 | |
US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
CN104027793A (zh) | 神经生长因子缓释纳米载体的制备及应用 | |
CN101422442A (zh) | 左乙拉西坦渗透泵控释片及其制备方法 | |
CN105496967B (zh) | 盐酸雷尼替丁控释干混悬剂及其制备方法 | |
CN1205938C (zh) | 具有改善哺乳动物微循环作用的产品 | |
CN101642443A (zh) | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 | |
EP2959891A1 (en) | Modified release pharmaceutical compositions of sofosbuvir and ribavirin | |
CN101642444A (zh) | 单硝酸异山梨酯双速渗透泵型控释制剂及其制备方法 | |
CN1247202C (zh) | 薯蓣皂苷口腔崩解片及其制备方法 | |
CN101869544A (zh) | 盐酸氨溴索控释干混悬剂及其制备方法 | |
RU2411035C2 (ru) | Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината | |
CN1123344C (zh) | 阿魏酸哌嗪缓释制剂 | |
CN1843368A (zh) | 一种灯盏花素长循环纳米脂质体及其制备方法 | |
CN108815128B (zh) | 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法 | |
CN1187054C (zh) | 含中药环维黄杨星d的渗透泵控释制剂及其制备方法 | |
CN101259112A (zh) | 盐酸沙格雷酯单层渗透泵控释制剂及其制备方法 | |
CN1395924A (zh) | 阿尼西坦缓释胶囊 | |
CN103599086B (zh) | 银杏叶总黄酮双层渗透泵控释片及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SPG mail (Tianjin) Medical Technology Co Ltd Assignor: Beijing Zhonghui Pharmaceutical Industry Co., Ltd. Contract record no.: 2010120000097 Denomination of invention: Control released osmotic pump prepn containing ligustrazine phosphate and its prepn process Granted publication date: 20050824 License type: Exclusive License Open date: 20030604 Record date: 20100810 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050824 Termination date: 20111220 |